The vitamin D analog, (23S)-25-dehydro-1␣-hydroxyvitamin D 3 -26,23-lactone , is an antagonist of the 1␣,25-dihydroxyvitamin D 3 [1␣,25(OH) 2 D 3 ] nuclear receptor (VDR)-mediated differentiation of human leukemia (HL-60) cells. To clarify whether TEI-9647 could function as an antagonist of 1␣,25(OH) 2 D 3 in vivo, we investigated in vitamin D-deficient (-D) rats the effects of single doses of TEI-9647 on several parameters of calcium metabolism modulated by 1␣,25(OH) 2 D 3 . TEI-9647 (50 g/kg iv) acting alone slightly, but significantly, stimulated intestinal calcium transport (ICA) and bone calcium mobilization (BCM) only at 8 h, but not at 24 h. In contrast, TEI-9647 dose-dependently inhibited ICA and BCM stimulated by an iv dose of 0.25 g/kg 1␣,25(OH) 2 D 3 after 24 h, but not after 8 h. With respect to serum PTH levels, the administration of either TEI-9647, 50 g/kg, or 1␣,25(OH) 2 D 3 , 0.25 g/kg, began to decrease the circulating levels by 4 h, which reached a nadir 24 h after administration.
But, when TEI-9647 and 1␣,25(OH) 2 D 3 were simultaneously administered to ϪD rats, the TEI-9647 dose-dependently reversed the inhibition of PTH secretion caused by 1␣,25(OH) 2 D 3 , 0.25 g/kg, at 8 and 24 h after the treatment. In separate experiments, the daily iv administration of 20 g/kg of TEI-9647 alone to ϩD rats for 2 weeks resulted in no significant changes in the prevailing serum Ca 2ϩ concentration. But doses of 1-20 g/kg of TEI-9647 in combination with 0.5 g/kg of 1␣,25(OH) 2 D 3 , for 2 weeks, dose-dependently and significantly suppressed the serum calcium concentration increase caused by the 1␣,25(OH) 2 D 3 . Collectively, these results show that TEI-9647 acting alone displays in vivo weak agonistic actions, but when administered in combination with 1␣,25(OH) 2 D 3 , is a potent antagonist of three genomic-mediated calcium metabolism parameters. We conclude that TEI-9647 can also function as an antagonist of 1␣,25(OH) 2 (1) . To date, 1␣,25(OH) 2 D 3 is considered to be the most potent metabolite of vitamin D 3 particularly with respect to three key calcium metabolism parameters; it stimulates intestinal absorption of calcium and bone calcium mobilization and inhibits the secretion of PTH. Each of these effects has been shown to be mediated via 1␣,25(OH) 2 D 3 acting on a target organ [intestine (2), bone (2) , and parathyroid gland (3, 4) ] nuclear vitamin D receptor (VDR)-mediated genomic responses (5, 6) .
In recent years, however, many new biological functions different from those mentioned above have been reported (7) ; these include inhibition of cell proliferation and induction of cell differentiation (8) , modulation of immunological responses (9 -11) , stimulation of insulin secretion (12, 13) , and neurobiological functions (14, 15) . 1␣,25(OH) 2 D 3 is believed to mediate biological responses as a consequence of its interaction both with a nuclear VDR to regulate gene transcription (16, 17) and with a putative cell membrane VDR (18) to generate rapid nongenomic actions (19) , including opening of voltage-gated calcium (9) and chloride channels (20) , and activation of mitogen-activated protein kinase (MAP kinase) (21 (22, 23) and of beagle dogs and normal adult humans under physiological conditions (24, 25) . This (23S,25R)-1␣,25(OH) 2 D 3 -26,23-lactone slightly stimulates intestinal calcium absorption but significantly decreases serum calcium concentrations in ϪD rats (26, 27) . The (23S,25R)-1␣,25(OH) 2 D 3 -26,23-lactone increases alkaline phosphatase activity and collagen synthesis in the osteoblastic MC3T3-El cells in vitro (28) and stimulates collagen synthesis and mineralization in vivo (29) . Also, in a rat experimental model of osteoporosis induced by ovariectomy, the (23S,25R)-1␣,25(OH) 2 D 3 -26,23-lactone significantly increased the bone formation rate in a dynamic histomorphometric study (30 Although it is clear that TEI-9647 and TEI-9648 inhibit the actions of 1␣,25(OH) 2 D 3 in vitro as described previously (31, 35) , it remains unclear whether they can also act as antagonists to the actions of 1␣,25(OH) 2 
Determinations of serum concentrations of vitamin D metabolites
Extraction of vitamin D metabolites in serum. Three-to-five milliliters of serum was diluted with two volumes of water and then 50 l of ethanol containing 5,000 dpm (50 pg) of [26,27- 2 D fraction from the Sephadex LH-20 column were next subjected to HPLC equipped with 4.6 ϫ 250 mm Zorbax SIL column (DuPont, Boston, MA) and were eluted with 5% isopropanol in n-hexane and 12% isopropanol in n-hexane at a flow rate of 1 ml/min, respectively. The (23S,25R)-1␣,25(OH) 2 D 3 -26,23-lactone fraction was separated and purified by HPLC equipped with 4.6 ϫ 250 mm Zorbax SIL column eluted with 3.5% methanol in dichloromethane. Each metabolite fraction was pooled for quantitation of serum concentrations.
Preparation of antisera IgG for calcitroic acid.
Calcitroic acid was conjugated with BSA by a mixed anhydride reaction according to Yamamoto et al. (41) . Antibodies to calcitroic acid were produced in four rabbits by repeated intradermal injections. The first immunization was performed with 500 g of conjugate emulsified in Freund's complete adjuvant and a booster injection was given in a similar manner at 3-week intervals. Antisera were tested frequently for specific binding to [26,27-methyl-3 H]1␣,25(OH) 2 D 3 . On the 7th day after the last booster (the 4th booster), blood was taken from the carotid artery, and the obtained antiserum was lyophilized. The antiserum dissolved in 0.1 m phosphate buffer (pH8.0) was applied on Protein A-Sepharose CL-4B (1.5 g). It was washed with 0.1 m phosphate buffer (pH7.0). The IgG fraction was eluted with 0.1 m glycine HCl buffer (pH 3.0). The eluent was dialyzed with 0.1 m phosphate buffer (pH 7.0) for 24 h at 4 C. After lyophilization, 40 mg of antisera IgG was obtained. For immunoassay, it was dissolved in 50% aqueous glycerine and the concentration was adjusted to 2.35 mg protein/10 ml and the resulting solution was stored a Ϫ20 C until use. 2 prepared from intestinal mucosa of vitamin d-deficient chicks were carried out as described previously (42, 43) . 2 23 lactone fraction from the serum sample to be assayed were dissolved in 20 l of absolute ethanol in 10 ϫ 75 mm glass tubes, and then added 100 l of 0.01% Triton X-100 containing phosphate buffer A (50 mm phosphate buffer, pH7.0 and 0.15 m NaCl) was added. Antisera IgG (200 l; 23.5 ng protein) for calcitroic acid in phosphate buffer A was added to each assay tube. The assay tubes were incubated for 24 h at 4 C. The free [26,27- with 500 32 l of dextran-coated charcoal. After incubation at 4 C for 15 min, each tube was centrifuged at 2,260 ϫ g for 10 min at 4 C, and 500 l of the supernatant was taken and mixed with 10 ml of 1,4-dioxane-based scintillator. The radioactivity was measured with a Beckman Coulter, Inc. liquid scintillation counter (Model LS6500) using an external standard. In this system, the sensitivity of the assay for (23S,25R)-1␣,25(OH) 2 D 3 -26,23-lactone was 2.5 pg/tube and measurement of 2.5 to 300 pg/tube was successfully carried out with good reproducibility.
Assay of 25-OH-D, 24R,25(OH)

RIA for (23S,25R)-1␣,25(OH)
Assay for intestinal calcium transport and bone calcium mobilization.
Male weanling Wistar rats were fed a vitamin d-deficient, low calcium diet (Ca 2ϩ , 0.0036%; P, 0.3%; Harlan Teklad Research Diet, Madison, WI) for 7 weeks. At the end of the seventh week, a group of three to five rats (each weighing about 100 g) received an iv injection of either 0.5 g/kg 1␣,25(OH) 2 D 3 or 50 g/kg TEI-9647 in 0.2 ml of 0.2% Triton X-100 saline solution. The rats were killed at the indicated time after the administration and the intestinal calcium transport and serum calcium concentrations were measured. The intestinal calcium transport assay using everted duodenal sacs was carried out by a standard method (44) . The serum Ca 2ϩ concentration was determined by the OCPC (O-cresolphthalein complexone) method (45) . Under the conditions of the assay elevations in serum calcium are a reflection of bone calcium mobilization (46) .
Determinations of PTH concentrations in rat serum. Serum PTH in rats was measured with immunoradiometric assay kits obtained from Immutopics (San Clemente, CA) according to their manual.
Statistical analysis
Data are expressed as mean Ϯ sem. The statistical significance of differences between groups was determined using a one-tailed Student's t test of the STAT VIEW program (Abacus Concepts Inc., Berkeley, CA). A level of P Ͻ 0.05 was considered statistically significant.
Experimental animals
All experimental procedures involving animals and the related protocols were approved by the Committee on Animal Care of the Teijin Institute for Biomedical Research Instruments, Inc. (Tokyo, Japan).
Results
The structures of 1␣,25(OH) 2 D 3 and the two lactone antagonists are shown in Fig. 1 .
Preparation of vitamin D-deficient rats
Vitamin D-deficient (-D) rats were used to investigate the effects of TEI-9647 on calcium metabolism in vivo. When male weanling Wistar rats (4-week-old) were fed a vitamin Ddeficient low calcium diet for 3 to 6 weeks, they developed hypocalcemia, hyperparathyroidism, mild alopecia, and rickets. Table 1 shows concentrations of calcium and four vitamin D metabolites in the serum of normal (ϩD) rats, and the ϪD rats fed a ϪD, low calcium diet for 7 weeks. The serum calcium concentrations of the ϪD rats were significantly decreased to about one-half that of the ϩD rats. Similarly, the serum concentrations of vitamin D metabolites in the ϪD rats were extremely diminished compared with those of the ϩD rats; particularly the serum concentration of 1␣,25(OH) 2 D 3 of the ϪD rats was 12-fold lower than the ϩD rats (5.1 Ϯ 3.6 pg/ml vs. 60.3 Ϯ 4.8 pg/ml). The serum concentration of (23S,25R)-1␣,25(OH) 2 D 3 -26,23-lactone in the ϪD rats was undetectable (Ͻ5 pg/ml), but in normal rats was 86.8 Ϯ 12.0 pg/ml. In data not presented, we have determined in normal Wistar rats the serum half-lives of single orally administered doses of TEI-9647 (50 g/kg) and 1␣,25(OH) 2 
Effects of TEI-9647 on parameters calcium metabolism in vitamin D-deficient rats
The biological activities of TEI-9647 were assessed in the ϪD rats that were fed a low calcium diet. Initially, a single dose of 50 g/kg TEI-9647 was used to test its intestinal calcium transport activity (Fig. 2) or bone calcium mobilization (Fig. 3) in comparison with that of 0.5 g/kg 1␣,25(OH) 2 D 3 . As shown in Fig. 2 , TEI-9647 acting as a weak agonist slightly but significantly stimulated intestinal calcium transport only 8 h after the administration. In contrast, 1␣,25(OH) 2 D 3 , slightly stimulated intestinal calcium transport at 4 h, reaching a maximum 8 h after the administration, and then its activity gradually decreased until 72 h. As shown in Fig. 3 , TEI-9647, acting as a weak agonist, slightly but significantly raised serum calcium levels after 8 h, however the serum calcium levels returned to the ϪD baseline level by 24 h. On the other hand, 1␣,25(OH) 2 D 3 acting alone generated a remarkable rise in serum calcium levels, which is in accord with previously published studies (26, 27) , demonstrating a potent action of 1␣,25(OH) 2 D 3 on bone calcium mobilization. (mg/100 ml) (ng/ml) (ng/ml) (pg/ml) (pg/ml) ϩD rats n ϭ 6 10.4 Ϯ 0. (Fig. 2) . Graded doses of TEI-9647 slightly stimulated intestinal calcium transport. The stimulation of intestinal calcium transport by TEI-9647 had only 1/1400 of the activity of 1␣,25(OH) 2 D 3 (Fig. 4) . Similarly, increasing doses of TEI-9647 resulted in a dose-response elevation of serum calcium concentrations 8 h after the administration. Bone calcium mobilization in the ϪD rats by TEI-9647 was only 1/377 that of 1␣,25(OH) 2 D 3 (Fig. 5 ). These results demonstrate that TEI-9647 acting alone can slightly stimulate intestinal calcium transport and bone calcium mobilization in the ϪD rats.
Effects of TEI-9647 on parameters of calcium metabolism mediated by 1␣,25(OH) 2 D 3
Next we examined the antagonistic effects of TEI-9647 on three parameters of calcium metabolism known to be mediated by 1␣,25(OH) 2 (E) or 50 g/kg TEI-9647 (F) in 0.2 ml of 0.2% Triton X-100-saline solution. At the indicated times, animals were decapitated and their duodena were used for the determination of intestinal calcium transport. The rate of intestinal calcium transport is represented by the ratio of 45 C 2ϩ in the serosal medium to 45 Ca 2ϩ in the mucosal medium. Each point is the mean Ϯ SEM of determinations from three to five rats.
FIG. 3.
Time-course response of bone calcium mobilization to 1␣,25(OH) 2 D 3 or lactone analog. Bone calcium mobilization was measured by an elevation in serum calcium levels induced in rats fed a low calcium diet by a single 500 ng/kg 1,25(OH) 2 D 3 (E) or 50 g/kg TEI-9647 (F). Rats fed a vitamin D-deficient low calcium diet received a single iv dose of compounds in 0.2 ml of 0.2% Triton X-100-saline solution. At the indicated times, animals were decapitated, blood was collected, and calcium was measured in the serum by the OCPC method. Data are expressed as mg Ca 2ϩ /100 ml of serum and are the mean Ϯ SEM of determinations from three to five rats .   FIG. 4 . Dose-response relationship between TEI-9647 and intestinal calcium transport in ϪD rats fed a low calcium diet. After 6 weeks on the vitamin D-deficient low calcium diet, rats were divided into groups of three to five animals. Each rat received a single iv injection of compound in 0.2% Triton X-100-saline solution. Control rats received only vehicle. Eight hours later, the animals were decapitated and intestinal calcium transport was measured as described in Materials and Methods. 155, vehicle ; E, 1␣,25-(OH) 2 D 3 , F, TEI-9647.
FIG. 5. Dose-response relationship between TEI-9647 and bone calcium mobilization, as measured by an elevation in serum calcium levels in deficient rats fed a low calcium diet. After 6 weeks on the vitamin D-deficient low calcium diet, rats were divided into groups of three to five animals; each rat received a single iv injection of compound in 0.2% Triton X-100-saline solution. Control rats received only vehicle. Eight hours later, animals were decapitated, blood was collected, and calcium was measured in the serum by the OCPC method. Data are expressed as mg Ca 2ϩ /100 ml of serum and are the mean Ϯ SEM of determinations from three to five rats. 155, vehicle ; E, 1␣,25(OH) 2 D 3 , F, TEI-9647.
g/kg TEI-9647 dose-dependently inhibited both intestinal calcium absorption and bone calcium mobilization mediated by 1␣,25(OH) 2 D 3 24 h after iv dose of 0.25 g/kg 1␣,25(OH) 2 D 3 , but could not inhibit these responses 8 h after the treatment (Table 2) . 1␣,25(OH) 2 D 3 is known to suppress the secretion of PTH and this action can be studied by measuring changes in the serum concentration of immunoreactive PTH (47, 48) . Table  3 indicates the time-course changes in the serum PTH levels in the ϪD rats iv dosed with TEI-9647 or 1␣,25(OH) 2 D 3 alone or in combination. When 50 g/kg TEI-9647 alone was iv administered to the ϪD rats, there resulted a rapid and marked decrease in serum PTH levels after 4 h which reached a nadir 24 h after the administration. Thereafter, the serum PTH levels gradually recovered to the control levels by 72 h. The same was true in the case of 0.5 g/kg 1␣,25(OH) 2 D 3 acting alone.
Serum calcium levels were only somewhat increased at 8 h after the administration of 50 g/kg TEI-9647, but after the administration of 0.5 g/kg 1␣,25(OH) 2 D 3 , peaked sharply at 8 h and then gradually decreased after 48 -72 h to the control levels. The serum PTH and serum calcium levels caused by 1␣,25(OH) 2 D 3 showed reciprocal changes with one another. Figure 6 presents results describing the consequences on the serum calcium concentration in the rat of the chronic iv administration over a 2-week interval of varying doses of TEI-9647, alone or in combination, with 1␣,25(OH) 2 D 3 . Figure 6A indicates that the daily iv administration of single doses of TEI-9647, over the range of 1-20 g/kg, does not result in a significant change in the normal serum calcium level. Thus, in this setting, TEI-9647 is neither an antagonist, nor even a weak agonist against the physiological serum concentrations of 1␣,25(OH) 2 D 3 (see Table 1 ). In contrast (Fig.  6B) , when TEI-9647 and 1␣,25(OH) 2 D 3 (0.5 g/kg) are given simultaneously to rats, TEI-9647 only at the high doses (10 -20 g/kg) is able to antagonize the hypercalcemic effects of the exogenously administered 1␣,25(OH) 2 D 3 .
Effects of chronic administration of TEI-9647 on serum calcium
Discussion
Recently, we demonstrated that the lactone analog, TEI-9647, which binds 65-fold more strongly to the VDR than the natural (23S,25R)-1␣,25(OH) 2 D 3 -26,23-lactone (31) , is an analog which can display varying proportions of weak agonist and strong antagonist properties to the VDR under in vitro conditions. Thus TEI-9647 in HL-60 cell lines in vitro, even at high concentrations, displayed predominantly only antagonist actions (49, 50) . But in other cell lines TEI-9647, while a potent antagonist of 1␣,25(OH) 2 D 3 /VDR, also displayed weak genomic agonist actions (35, 51) . Therefore, we have investigated whether TEI-9647 could function as a vitamin D agonist or antagonist in vivo in ϪD rats.
We used ϪD rats to assess three parameters of calcium metabolism of TEI-9647 under both vitamin D-deficient and -replete conditions. When the rats were fed a vitamin D-deficient, low calcium diet for 7 weeks, their serum calcium levels and all vitamin D metabolites concentrations were extremely low compared with those of normal ϩD rats (Table 1) . When TEI-9647 was iv administered to these ϪD rats, TEI-9647 slightly but significantly stimulated intestinal calcium absorption and bone calcium mobilization after 8 h, with a potency of only 1/1400 and 1/377 that of 1␣,25(OH) 2 D 3 , respectively (Figs. 4 and 5) . On the other hand, TEI-9647 dose-dependently inhibited intestinal calcium absorption and bone calcium mobilization 24 h after an iv dose of 0.25 g/kg 1␣,25-(OH) 2 D 3 , but could not entirely inhibit them after 8 h (Table 2) .
It has previously been reported that the time course of 1␣,25(OH) 2 D 3 -induced intestinal calcium transport is biphasic with peaks of stimulation early at 4 -8 h and late at 24 h, which may be reflective of two mechanistically different processes (52) (53) (54) . The first response by 1␣,25(OH) 2 D 3 may initially act by increasing the permeability of the brush border membranes to calcium and may be independent of any de novo genomic actions (55, 56). The second slower response After 8 weeks on the vitamin D-deficient, low calcium diet, rats were divided into groups of three or five animals; each rat received a single iv dose of compound in 0.2% Triton X-100-saline solution. Control rats received only vehicle. The indicated times later, the rats were decapitated and serum PTH concentrations and serum calcium concentrations were measured as described in Materials and Methods. Data are expressed as mean Ϯ SEM. Significantly different from controls:
a P Ͻ 0.05, b P Ͻ 0.001, and c P Ͻ 0.01. (5) . In this paper, we showed that TEI-9647, acting alone as an agonist, decreased immunoreactive PTH levels over 4 to 48 h with no change in serum calcium, when the analog is iv administered to ϪD hypocalcemic rats (Tables 3 and 4) . Similar weak agonist actions of TEI-9647 were noted in the ϪD rats with respect to stimulation of intestinal calcium absorption and bone calcium mobilization (Figs. 3 and 4) WAF1,CIP1 in HL-60 cells, and activation of the luciferase reporter assay in COS-7 cells and Saos-2 cells transfected with plasmids containing the VDRE of the human and rat 25-OH-D 3 -24-hydroxylase gene and cDNA of human VDR (31, 35) . Moreover, very recently we clearly demonstrated that TEI-9647 inhibits the heterodimer formation between VDR and RXR, and between VDR and SRC-1 in Saos-2 cells (35) . Collectively, these results and also molecular modeling of the VDR with TEI-9647 (70), strongly suggest that our novel (23S,25R)-1␣,25(OH) 2 D 3 -26,23-lactone analog, TEI-9647, is the first documented antagonist of 1␣,25(OH) 2 D 3 VDR/VDRE mediated genomic action (31, 35) . Importantly we have shown in this report that TEI-9647 is also an antagonist in vivo of three 1␣,25(OH) 2 D 3 calcium metabolism parameters. At present, we are working on further studies concerning the mode of antagonistic action of the weak agonist/strong antagonist TEI-9647. Blood was collected at 24 h after the final administrations and the serum was obtained. Then, total serum calcium was determined as described in Experimental procedures. Each point is the mean Ϯ SEM of determinations from five rats. ## P Ͻ 0.01 (significantly different from the control). *, P Ͻ 0.05, and **, P Ͻ 0.01 (significantly different from the 0.5 g/kg of 1␣,25(OH) 2 D 3 group).
